Boston Scientific Corporation ($BSX) Stock Forecast: Down 5.1% Today

What is Boston Scientific Corporation?

Boston Scientific Corporation (NYSE: BSX) is a leading medical technology company that develops and manufactures innovative medical devices used in various medical specialties.

Why is Boston Scientific Corporation going down?

BSX stock is down 5.1% on Mar 30, 2026 15:45

• Boston Scientific (BSX) experienced a strong bearish movement today.
• The bearish trend could be attributed to the market's reaction to the upcoming conference call discussing the company's first-quarter 2026 results. Investors might be cautious or uncertain about the financial performance and business highlights to be revealed during the call.
• Additionally, the news about the FDA 510(k) clearance for Boston Scientific's Asurys Fluid Management System targeting kidney stone procedure risks might not have been impactful enough to offset the overall negative sentiment surrounding the stock.
• The reaffirmation of a "Strong Buy" rating for First Watch Restaurant Group by Raymond James, despite recent stock decline, could have also diverted investor attention away from Boston Scientific, contributing to the bearish movement.

BSX Price Chart

BSX Technical Analysis

BSX News

Raymond James reiterates First Watch stock Strong Buy on valuation

Raymond James has reiterated a "Strong Buy" rating and a $20.00 price target for First Watch Restaurant Group (NASDAQ:FWRG) despite recent management changes and stock decline. The firm noted the recent termination of the COO is not performance-related, and the stock is currently trading at all-time low valuation metrics, suggesting it's oversold. Other analysts have a mixed outlook, with price targets ranging from $15 to $24.

https://www.investing.com/news/analyst-ratings/raymond-james-reiterates-first-watch-stock-strong-buy-on-valuation-93CH-4588092

4,700 cancer providers can now order Abbott tests in their records system

Abbott and Flatiron Health have integrated Abbott's Precision Oncology portfolio into Flatiron's OncoEMR platform, allowing 4,700 providers at over 1,600 community cancer centers to order Abbott tests and receive results directly within their clinical workflow. This integration is designed to streamline the process, reduce administrative burden, and accelerate informed treatment decisions for cancer patients. The available tests include Oncotype DX Breast Recurrence Score®, OncoExTra®, Oncodetect®, and Riskguard®, aiming to provide a unified experience for clinicians.

https://www.stocktitan.net/news/ABT/abbott-expands-access-to-precision-oncology-portfolio-through-s94qbijartvf.html

Boston Scientific announces conference call discussing first quarter 2026 results

Boston Scientific Corporation will host a webcast conference call on Wednesday, April 22, 2026, at 8:00 a.m. ET to discuss its financial results and business highlights for the first quarter ended March 31, 2026. The company will issue a news release with these financial results prior to the call. A live webcast and replay will be available on the company's investor relations website.

https://finviz.com/news/340768/boston-scientific-announces-conference-call-discussing-first-quarter-2026-results

Boston Scientific announces conference call discussing first quarter 2026 results

Boston Scientific (NYSE: BSX) will host a webcast conference call on Wednesday, April 22, 2026, at 8:00 a.m. ET to discuss its financial results and business highlights for the first quarter ending March 31, 2026. Prior to the call, the company will release its financial results. The event will feature Chairman and CEO Mike Mahoney and EVP and CFO Jon Monson, with a live webcast and replay available on their investor relations website.

https://ca.finance.yahoo.com/news/boston-scientific-announces-conference-call-120000632.html

New Boston Scientific system targets kidney stone procedure risks

Boston Scientific (NYSE: BSX) has received FDA 510(k) clearance for its Asurys Fluid Management System, designed to regulate intrarenal pressure during endoscopic urologic procedures, especially for kidney stone treatment. This system integrates with the LithoVue Elite to improve patient safety by minimizing complications like sepsis and streamlines workflows for urologists. A limited U.S. market release is set to begin soon, expanding Boston Scientific's StoneSmart ecosystem.

https://www.stocktitan.net/news/BSX/boston-scientific-receives-fda-clearance-for-the-asurys-tm-fluid-tt9va8d4p1y9.html

Trending Today

Quidelortho Corpoation ($QDEL) Stock Forecast: Down 6.5% Today

Arista Networks Inc. ($ANET) Stock Forecast: Up 5.3% Today

UnitedHealth Group Incorporated (DE) ($UNH) Stock Forecast: Up 10.7% Today

Cognex Corporation ($CGNX) Stock Forecast: Up 5.2% Today

MicroVision Inc. ($MVIS) Stock Forecast: Down 8.9% Today

Lucid Motors Inc. ($LCID) Stock Forecast: Down 5.5% Today

TKO Group Holdings Inc ($TKO) Stock Forecast: Down 5.1% Today

Lemonda Inc. ($LMND) Stock Forecast: Down 6.7% Today

CVS Health Corporation ($CVS) Stock Forecast: Up 6.2% Today

Intel Corporation ($INTC) Stock Forecast: Up 5.0% Today

Boston Scientific Corporation Price History

17.11.2025 - BSX Stock was up 5.2%

• A notable decrease in Thurston Springer Miller Herd & Titak Inc.'s stake might have sparked some initial investor concerns. However, the positive Q3 outcomes and analyst ratings likely alleviated apprehensions, bolstering confidence in the company's future outlook.
• Insider sales totaling $14.23 million could be viewed as stock-profit realization by company insiders, showing their faith in the current stock prices and growth potential.
• Today's bullish trend in BSX's stock price seems to stem from strong financial performance, positive analyst evaluations, and investor trust in the company's strategic vision.

22.09.2025 - BSX Stock was up 5.0%

• Boston Scientific (BSX) reported strong Q3 earnings with a 19% growth in EPS, surpassing market expectations. This positive financial performance, along with raising their 2025 sales and EPS outlook, contributed to the bullish movement in the stock.
• The acquisition of Nalu Medical Inc., a maker of minimally invasive devices for chronic pain treatment, for approximately $533 million also boosted investor confidence in Boston Scientific's growth prospects.
• The company's robust cardiovascular performance, driven by innovative products like WATCHMAN FLX Pro and AGENT DCB, is expected to further enhance its earnings potential, attracting more investors to the stock.

02.08.2025 - BSX Stock was up 1.5%

• BSX had a strong bullish movement today, potentially driven by the company's consistent outperformance in the market over the past 5 years, with an average annual return of 20.59%.
• The comparison with other medical stocks may have highlighted BSX's strong performance, attracting investors looking for growth opportunities in the sector.
• Investors might be optimistic about BSX's future prospects, considering its track record of innovation and market leadership in the medical technology industry.

04.01.2026 - BSX Stock was down 13.8%

• Boston Scientific's stock (BSX) saw a significant 17% decline post its Q4 2025 earnings and revenue report.
• Despite surpassing expectations for the quarter, the stock plummeted due to lower-than-anticipated guidance for Q1 2026, raising concerns about the company's short-term outlook.
• The announcement of a $14.5 billion acquisition of Penumbra (PEN) potentially added to investor unease and the subsequent drop in BSX's stock value.
• The market's response indicates a strong emphasis on future guidance and growth prospects, leading to the sell-off of BSX shares despite positive current performance indicators.

04.01.2026 - BSX Stock was down 17.7%

• Reported an increase in profit and sales spurred by strong performance in cardiovascular and MedSurg units, but issued soft guidance for the future period, leading to a decline in share price.
• Despite exceeding earnings expectations, the stock fell significantly due to a disappointing outlook for the current quarter. Cautious 2026 revenue forecast and profit projections, slightly below expectations, contributed to the downtrend.
• Market responded unfavorably to the company's forecast of slower organic revenue growth in 2026, despite exceeding analyst estimates in the fourth quarter. This conservative outlook, alongside the integration of a major acquisition, triggered investor concerns about future growth prospects.

30.02.2026 - BSX Stock was down 5.1%

• Boston Scientific (BSX) experienced a strong bearish movement today.
• The bearish trend could be attributed to the market's reaction to the upcoming conference call discussing the company's first-quarter 2026 results. Investors might be cautious or uncertain about the financial performance and business highlights to be revealed during the call.
• Additionally, the news about the FDA 510(k) clearance for Boston Scientific's Asurys Fluid Management System targeting kidney stone procedure risks might not have been impactful enough to offset the overall negative sentiment surrounding the stock.
• The reaffirmation of a "Strong Buy" rating for First Watch Restaurant Group by Raymond James, despite recent stock decline, could have also diverted investor attention away from Boston Scientific, contributing to the bearish movement.

04.01.2026 - BSX Stock was down 15.4%

• Boston Scientific reported strong Q4 2025 earnings, beating expectations in both adjusted EPS and revenue. However, the stock plummeted due to a disappointing 2026 revenue forecast, which fell short of analyst consensus.
• The company's cautious outlook for 2026, including a projected deceleration in organic revenue growth and integration concerns related to the Penumbra acquisition, contributed to investor concerns and the subsequent bearish movement in the stock.
• Despite the positive Q4 results, the market reacted negatively to the revenue shortfall, highlighting the importance of forward-looking guidance and market sentiment in determining stock performance.
• Boston Scientific's stock underperformance in premarket trading, compared to the broader market trend, further emphasizes the impact of company-specific factors on investor confidence and stock valuation.

04.01.2026 - BSX Stock was down 15.6%

• Despite Boston Scientific beating Q4 2025 earnings and revenue estimates, the stock experienced a significant 17% drop due to weaker-than-expected guidance for Q1 2026. This disappointing outlook for the immediate future led to a bearish market movement.
• The slowdown in the growth of the electrophysiology business, particularly in the U.S. market, raised concerns among analysts and investors, contributing to the stock price decline.
• The acquisition of Penumbra for $14.5 billion could have also impacted investor sentiment, as the market may be uncertain about the potential synergies and outcomes of this significant move.
• The cautious outlook provided by Boston Scientific despite reporting increased profit and sales suggests that investors are focusing more on the company's future prospects and guidance, which in this case, did not meet expectations, leading to the bearish movement in the stock.

15.09.2025 - BSX Stock was up 4.3%

• BSX closed at $95.41 after a -1.92% shift in the latest trading session, showing a predominantly bullish trend.
• Comparisons with other value stocks like PAHC imply that BSX may offer better value, attracting more investors and positively impacting the market.
• The minor decline in the stock price could be linked to profit-taking following notable gains, yet the outlook for BSX remains optimistic.

08.11.2025 - BSX Stock was down 2.3%

• The bearish movement in BSX stock today could be linked to the negative sentiment following a recent FDA panel vote against a novel shunt implant by Johnson & Johnson for heart failure. This development might have raised concerns about the regulatory landscape for medical device firms, thus influencing the stock price of BSX.
• Although a bullish case is made for BSX focusing on revenue growth and innovation potential, the market sentiment, largely influenced by the FDA panel vote, may have overshadowed these positive aspects.
• Institutional investors showing increased interest in Zimmer Biomet Holdings, Inc. (ZBH) could have diverted attention and financial resources away from BSX, contributing to the downward trend in BSX stock.
• The emergence of Tuodao Medical in China, with a specialty in surgical robot technology, could have further impacted BSX as investors potentially shifted focus towards emerging competitors in the medical technology industry.

06.07.2025 - BSX Stock was down 2.2%

• The bearish movement in BSX today could be attributed to investors comparing the stock with GE HealthCare Technologies (GEHC) and potentially finding more value in the latter.
• The overly optimistic views of Wall Street analysts on BSX might have raised concerns among investors about the stock's actual performance, leading to a sell-off.
• Investors may have also reacted to broader market trends or specific industry news impacting medical product companies, causing a negative sentiment towards BSX in today's trading session.

01.09.2025 - BSX Stock was down 3.8%

• The bearish movement in Boston Scientific's stock today could be attributed to profit-taking by investors after a prolonged period of outperformance.
• The comparison between Boston Scientific and Phibro Animal Health in terms of value might have led some investors to shift their focus, causing a temporary dip in BSX stock.
• Market sentiment or broader economic factors could also have played a role in the bearish movement of Boston Scientific's stock today.